Clinical Evaluation of an NVTIA GABA-Lysine Calcium Preparation for Promoting Calcium Absorption

Abstract

Background: Improving calcium bioavailability requires more than simply increasing elemental calcium content. In this study, we evaluated an NVTIA GABA-lysine calcium preparation that couples a modified algal-calcium microsphere, an absorption-promoting inclusion module, a calcium-deposition cofactor module, and antioxidant protection. We then matched our bench findings with published human trials that are directly relevant to lysine-assisted calcium handling, algae-derived calcium, calcium plus vitamin D, and vitamin K-guided mineral utilization. Methods: We summarized our bench dataset on active retention, simulated intestinal dispersion, gastric-acid integrity, particle-size distribution, and short-term stability. We then incorporated published human studies on L-lysine and calcium metabolism, calcium lysinate, active absorbable algal calcium, marine algae-derived calcium, calcium plus vitamin D, vitamin K2 add-on therapy, and casein phosphopeptide-containing calcium preparations. Results: In our bench dataset, core active retention reached 98.5%–99.0% versus 82.3% in the comparator, K2MK7/VD2 retention reached 98.5%–98.8% versus 86.7%, and complete dispersion in simulated intestinal fluid occurred within 2–3 minutes versus >8 minutes in the comparator. Published human evidence showed that L-lysine supplementation increased intestinal calcium absorption and improved renal calcium conservation in osteoporotic patients; calcium lysinate achieved a reported relative oral bioavailability of 223.15% in osteopenic adults; active absorbable algal calcium demonstrated higher fractional calcium absorption than calcium carbonate in postmenopausal women (23.1 ± 6.4% vs 14.7 ± 6.4%, p = 0.006); and marine algae-derived calcium produced more prolonged suppression of serum parathyroid hormone than calcium carbonate in a crossover pilot trial. Calcium plus vitamin D reduced parathyroid hormone and bone-resorption markers in older women, whereas long-term MK-7 add-on therapy strongly improved osteocalcin carboxylation but did not improve bone mineral density or bone-turnover markers. By contrast, a randomized crossover study found that casein phosphopeptides did not meaningfully improve fractional calcium absorption.N Conclusions: Our formulation logic aligns best with the human evidence supporting lysine-assisted calcium uptake, algae-derived calcium delivery, and calcium/vitamin-guided mineral handling. The combined GABA-lysine calcium system therefore warrants direct randomized testing with fractional calcium absorption and bone-turnover markers as primary biological endpoints.